Table 2.
Incidence of hepatocellular carcinoma by antiviral agents.
| Group | Total | Person-year | HCC (–) | HCC (+) | Incidence rate (95% CI) | Incidence rate ratio (95% CI) | p value∗ | |
|---|---|---|---|---|---|---|---|---|
| All users | ||||||||
| Before PMS | TAF | 24,979 | 61,119 | 24,979 (97.27) | 701 (2.73) | 11.47 (10.65–12.35) | 1 (ref) | — |
| TDF | 25,837 | 74,143 | 25,837 (95.86) | 1,115 (4.14) | 15.04 (14.18–15.95) | 1.31 (1.19–1.44) | <0.001 | |
| ETV | 22,294 | 62,136 | 22,294 (96.18) | 885 (3.82) | 14.24 (13.33–15.21) | 1.24 (1.12–1.37) | <0.001 | |
| After PMS | TAF | 17,537 | 41,210 | 17,027 (97.09) | 510 (2.91) | 12.38 (11.35–13.50) | 1 (ref) | — |
| TDF | 17,536 | 48,206 | 16,791 (95.77) | 742 (4.23) | 15.39 (14.32–16.54) | 1.24 (1.11–1.39) | <0.001 | |
| ETV |
17,535 |
48,530 |
16,889 (96.32) |
646 (3.68) |
13.31 (12.32–14.38) |
1.08 (0.96–1.21) |
0.219 |
|
| Cirrhosis (+) | ||||||||
| Before PMS | TAF | 6,188 | 14,615 | 5,811 (93.91) | 377 (6.09) | 25.79 (23.32–28.53) | 1 (ref) | — |
| TDF | 5,192 | 13,890 | 4,596 (88.52) | 596 (11.48) | 42.91 (39.60–46.49) | 1.66 (1.46–1.89) | <0.001 | |
| ETV | 4,726 | 12,910 | 4,203 (88.93) | 885 (11.07) | 40.51 (37.18–44.13) | 1.57 (1.38–1.79) | <0.001 | |
| After PMS | TAF | 3,249 | 80,98 | 3,249 (92.99) | 245 (7.01) | 30.25 (26.69–34.29) | 1 (ref) | — |
| TDF | 3,120 | 9,454 | 3,120 (89.3) | 374 (10.70) | 39.56 (35.75–43.78) | 1.31 (1.11–1.54) | 0.001 | |
| ETV |
3,119 |
9,738 |
3,119 (89.27) |
375 (10.73) |
38.51 (34.80–42.61) |
1.27 (1.08–1.50) |
0.003 |
|
| Cirrhosis (-) | ||||||||
| Before PMS | TAF | 19,492 | 46,503 | 19,168 (98.34) | 324 (6.09) | 6.97 (6.25–7.77) | 1 (ref) | — |
| TDF | 21,760 | 60,252 | 21,241 (97.61) | 519 (11.48) | 8.61 (7.90–9.39) | 1.24 (1.08-1.42) | 0.003 | |
| ETV | 18,453 | 49,225 | 18,091 (98.04) | 362 (1.96) | 7.35 (6.63–8.15) | 1.06 (0.91-1.23) | 0.480 | |
| After PMS | TAF | 14,102 | 33,267 | 13,829 (98.06) | 273 (1.94) | 8.21 (7.29–9.24) | 1 (ref) | — |
| TDF | 14,101 | 38,769 | 13,723 (97.32) | 378 (2.68) | 9.75 (8.81–10.78) | 1.19 (1.02–1.39) | 0.030 | |
| ETV | 14,100 | 38,942 | 13,827 (98.06) | 273 (1.94) | 7.01 (6.23–7.89) | 0.85 (0.72–1.01) | 0.066 | |
∗
p values were evaluated using Poisson regression analysis. ETV, entecavir; HCC, hepatocellular carcinoma; PMS, propensity score matching; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.